German Drugmakers Fear Losses On Italian Market

21 July 1996

German pharmaceutical manufacturers with subsidiaries in Italy see their position on the Italian market threatened by the new cost-cutting measures which came into force as the Marketletter went to press this week (Marketletter July 15).

Under the new decree, the costs of drugs will only be reimbursed by the social security system if the drug companies are prepared to align their prices with the cheapest competing products based on the same active principles. In addition, some 900 products have been removed from the Prontuario, the list of reimbursable products. If none of the drug companies responds to the government's request to lower their prices, an estimated 1,200 products could disappear from the reimbursable sector of the market.

The government's aim is to save about $700 million on the drugs budget, in order to help towards reducing the public-sector deficit and meeting the Maastricht criteria for European monetary union.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight